MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • C9ORF72 intermediate repeat copies as a rare genetic cause of atypical Parkinsonian syndromes or Parkinson’s disease complicated by psychosis in a Sardinian population

    M. Meloni, A. Cannas, P. Solla, M.M. Mascia, G. Orofino, R. Farris, D. Ciaccio, E. Binaghi, M.R. Murru, F. Marrosu (Cagliari, Italy)

  • CAG repeat length and weight loss in pre-manifest Huntington’s disease

    C.F. Kutz, L.J. Adams (Colorado Springs, CO, USA)

  • CAG repeats number of ATXN7 in SCA7 patients and normal population in Japan

    Y. Adachi, R. Shimoyama (Matsue, Japan)

  • Can a leopard changes its spots? How impulse control disorder affects subthalamic stimulation paradigm

    N.G. Pozzi, B. Minafra, M. Picascia, R. Zangaglia, D. Servello, C. Pacchetti (Pavia, Italy)

  • Can body worn cameras help us understand the complex relationship between physical activity and falls in people with Parkinson’s?

    K. Baker, M. Harvey, J. Monaghan, L. Rochester (Newcastle Upon Tyne, United Kingdom)

  • Can deep brain stimulation implantation cause multiple system atrophy? A retrospective review of MSA patients

    E.A. Coon, B.T. Klassen, J.E. Ahlskog, P.A. Low, W. Singer (Rochester, MN, USA)

  • Can hospital admissions predict mortality in Parkinson’s?

    B. Mohamed, N. Leopold, C. Thomas (Cardiff, United Kingdom)

  • Can intraoperative clinical testing really predict the effects of deep brain stimulation in the subthalamic nucleus?

    J. Blume, J. Schlaier, F. Zeman, E. Rothenfußer, A. Brawanski, U. Bogdahn, M. Lange (Regensburg, Germany)

  • Can quantitative analysis of the “finger-to-nose test” discern between EOA and other conditions of coordination impairment?

    O.E. Martinez Manzanera, T. Lawerman, D.A. Sival, N. Maurits (Groningen, Netherlands)

  • Can stimulation of deep brain tissue improve the expression of the mouth in Parkinson’s disease patients?

    M.V. Alvarez, P.M. Grogan (San Antonio, TX, USA)

  • Can treadmill training facilitate the dual-task gait in Parkinson’s disease?

    A.V.C. Sousa, L.M.M. Santiago, R.E.O. Silva, A.P. Spaniol, D.A. Oliveira, É.R.V.P. Galvão, T.S. Ribeiro, A.R.R. Lindquist (Natal, Brazil)

  • Cancer comorbidity among PD patients; a population based large-scale cohort study

    R. Gurel, N. Giladi, V. Rozani, T. Gurevich, B. El-Ad, B. Hemo, J. Tsamir, C. Peretz (Tel Aviv, Israel)

  • Cancer in Machado Joseph disease patients – Low frequency as a cause of death

    L.B. Jardim, G.N. Souza, N. Kersting, T.A. Gonçalves, D. Pacheco, M.L. Saraiva-Pereira, J.A. Saute (Porto Alegre, Brazil)

  • Cardiometabolic syndrome and risk of Parkinson’s disease: A case-control study in Mexican population

    G. Parra-López, L. Bazán-Rodríguez, M. Rodríguez-Violante, A. Cervantes-Arriaga, A. Jorge de Saráchaga, M. Escobar-Barrios, E. Carreón-Bautista (Mexico City, Mexico)

  • Cardiovascular and cerebrovascular disorders are associated with a higher prevalence of parkinsonism: Data from a neuroepidemiologic community-based survey

    S.M. Fereshtehnejad, M. Shafieisabet, A. Rahmani, A. Delbari, J. Lökk (Stockholm, Sweden)

  • Caring for the majority: Telemedicine management of Parkinson’s disease (PD) in underserved populations in People’s Republic of China: A randomized trial

    P.B. Chan, S. Liu, Z. Gu, J. An, C.M. Tanner (Beijing, People's Republic of China)

  • Carrier mediated delivery system bearing dopamine for effective management of parkinsonism

    V. Bhargava, S. Bhargava (Kanpur, India)

  • Catechol-o-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson’s disease

    Y. Zhang, Y. Zhang, K. Nie, S. Feng, L. Wang, J. Zhao, Z. Huang, L. Wang (Guangzhou, People's Republic of China)

  • Categories of psychogenic movement disorders to functional blepharospasm

    J. Gazulla (Zaragoza, Spain)

  • Cell-surface expression of dopamine transporter facilitates the uptake of α-synuclein

    J. Kobayashi, T. Hasegawa, S. Yoshida, N. Sugeno, R. Oshima, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

  • Cellular senescence induced by paraquat drives neuropathology associated with Parkinson’s disease

    S.J. Chinta, G. Woods, M. Demaria, J. Campisi, J.K. Andersen (Novato, CA, USA)

  • Cerebellar ataxia and pregnancy

    N. Hidarilak, T. Yacoubian (Birmingham, AL, USA)

  • Cerebellar atrophy in Parkinson’s disease and its implication for network connectivity

    J.M. Shine, C. O'Callaghan, M. Hornberger, G.M. Halliday, S.J.G. Lewis (Palo Alto, CA, USA)

  • Cerebellar GABA in essential tremor and dystonic tremor: A MR spectroscopy study

    P. Panyakaew, H.J. Cho, S. Horovitz, M. Hallett (Bethesda, MD, USA)

  • Cerebellar GABA-A receptor activity is inversely correlated with gait speed in Parkinson’s disease

    N.I. Bohnen, K.A. Frey, R.A. Koeppe, P.J.H. Scott, M.L.T.M. Muller (Ann Arbor, MI, USA)

  • Cerebellar gray matter alterations in Huntington disease: A voxel-based morphometry study

    P. Azevedo, R. Guimarães, L. Piovesana, C. Piccinin, M.C. Arci, L. Villany, L. Campos, G. Pinheiro, J. Zuiane, A. Amato Filho, F. Cendes, Í. Lopes-Cendes, A. D'Abreu (Campinas, Brazil)

  • Cerebellar learning and its modifiability by alcohol in myoclonus-dystonia

    A. Weissbach, E. Werner, T. Bäumer, D. Timmann, N. Brüggemann, V. Tadic, C. Klein, A. Münchau (Lübeck, Germany)

  • Cerebral vasoreactivity in Parkinson’s disease and multiple system atrophy: A pilot study

    E. Indelicato, F.E. Pontieri, D. Benincasa, A. Fanciulli, F. Orzi, M. Giovannelli, G. Sette (Rome, Italy)

  • Cerebrospinal fluid biomarkers in Parkinson’s disease and associated cognitive impairment

    M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

  • Cervical dystonia and quality of life

    S. Tomic, I. Petkovic, T. Pucic, S. Juric, S. Butkovic Soldo (Osijek, Croatia)

  • Cervical dystonia associated to Wallenberg syndrome

    I. Parees, M. Romeral, D. Mayo, D. Toledo, M.E. Garcia, J. Matias-Guiu, A. Marcos, J. Porta-Etessam (Madrid, Spain)

  • Cervical dystonia preceding Parkinson´s disease – Continuum – coincidence or epiphenomenon–Report of 3 cases

    J. Walch, G. Kägi (St. Gallen, Switzerland)

  • Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease

    A.Y. Son, M.C. Biagioni, E. Pirraglia, A. DiRocco (New York, NY, USA)

  • Changes in mood and behavior following DBS – Measurement by self-reported questionaires

    I. Galazky, S. Hubich, T. Zähle, J. Voges (Magdeburg, Germany)

  • Changes in motor symptoms of Parkinson’s disease: 2-year follow-up of 735 cases

    P. Martinez-Martin, C. Rodriguez-Blazquez, A. Rizos, K.R. Chaudhuri, NILS, EUROPAR and MDS Non-Motor PD Study Groups (Madrid, Spain)

  • Changes in serum amino acid levels with progression of Parkinson’s disease

    M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

  • Changes of brain structure and cognition in individuals with possible prodromal Parkinson’s disease

    M. Heldmann, J. Heeren, L. Rauch, C. Klein, T.F. Münte, M. Kasten, N. Brüggemann (Lübeck, Germany)

  • Changes of speech after neurostimulation for Parkinson’s disease with early fluctuations: A 2-years randomized controlled trial (earlystim-speech)

    S. Pinto, A. Nebel, R. Espesser, J. Rau, P. Maillochon, O. Krack, K. Knudsen, A. Ghio, O. Niebuhr, Y. Agid, M. Schüpbach, G. Deuschl (Aix-en-Provence, France)

  • Characterisation of the A30P mutation in alpha-synuclein gene in patient-derived cellular model of Parkinson’s disease

    B.F.R. Santos, P.A. Barbuti, I. Boussaad, A. Hummel, R. Krüger (Belval, Luxembourg)

  • Characteristics of drop outs in a longitudinal study on individuals at risk for a neurodegenerative disorder

    U. Suenkel, S. Heinzel, A.K. von Thaler, F. Metzger, G.W. Eschweiler, I. Liepelt-Scarfone, W. Maetzler, D. Berg (Tübingen, Germany)

  • Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)

    C. Francois, K. McLeod, A. Duhig, A. Ogbonnaya, A. Quillen, J. Cannon, B. Padilla, C.A. Shibao, I. Biaggioni (Deerfield, IL, USA)

  • Characteristics of the interaction between different toxic aggregated species of alpha-synuclein and cell membrane

    A.T. Marvian, D. Morshedi, F. Aliakbari, H. Ghapani, M. Nasuti (Tehran, Islamic Republic of Iran)

  • Characterization and quantitative analysis of prelemniscal radiations in Parkinson´s disease

    M.G. Garcia-Gomar, I. Vaca-Palomares, M. Esqueda, J. Soto, J.D. Tournier, L. Concha, F. Velasco (Queretaro, Mexico)

  • Characterization of burning mouth syndrome in patients with Parkinson’s disease

    P.J. Blanchet, D. Bonenfant, P.H. Rompré, N. Rei, N. Jodoin, V.L. Soland, V. Rey, C. Brefel-Courbon, F. Ory-Magne, O. Rascol (Montreal, QC, Canada)

  • Characterization of European longitudinal cohort studies in Parkinson’s disease – Report of the JPND working group BioLoC-PD

    S. Lerche, I. Liepelt-Scarfone, G. Alves, P. Barone, S. Behnke, Y. Ben-Shlomo, H. Berendse, D. Burn, R. Dodel, D. Grosset, M. Hu, M. Kasten, R. Krüger, W. Maetzler, B. Mollenhauer, W. Oertel, U. Walter, K. Wirdefeldt, D. Berg (Tübingen, Germany)

  • Characterization of sleep disturbances in a prospective population-based cohort to investigate Parkinson’s disease

    S. Tunc, J. Hampf, E.J. Vollstedt, K. Hückelheim, E. Warrlich, C. Kritzinger, C. Bibergeil, J. Graf, C. Klein, M. Kasten (Lübeck, Germany)

  • Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease

    G. Gomez, M. Bordone, S.I. Sanz-Blasco, M.A. Bernardi, J.E. Ferrario, I.R.E. Taravini, M.G. Murer, O.S. Gershanik (Buenos Aires, Argentina)

  • Chewing-induced blepharospasm in Parkinson’s disease

    E. Sasse, L.F. Vasconcellos, M. Spitz (Rio de Janeiro, Brazil)

  • Children with idiopathic tics reveal additional features of hyperkinetic movement disorders

    P.F. Sinnige, R. Brandsma, W. Eggink, M.J. Kuiper, I.J. Lunsing, M. Boon, C.C.S. Delnooz, M.E. van Egmond, O.G.F. Sinnige, J.J. de Vries, P.J. Hoekstra, D.A. Sival (Groningen, Netherlands)

  • Children with intractable temporal and extratemporal seizures: Correlation of the MR spectroscopy and EEG findings in the surgical planning

    M.M. Arnaout, S.S. Desoky, I.A. Lebda, A.A. Bessar, M.I. Fathy, E.H. Zidan, H.A. Hassan (Zagazig, Egypt)

  • Chin EMG variance and dream-enactment behavior during polysomnography in Parkinson’s disease

    Y. Shen, K.P. Xiong, C.J. Mao, C.F. Liu (Suzhou, People's Republic of China)

  • Chorea – Ballism drug induced in replacement treatment with thyroid hormones – Case presentation

    M. Sabau (Oradea, Romania)

  • Chorea-acanthocytosis: The first described clinical case in Ukraine

    Y.O. Trufanov (Kyiv, Ukraine)

  • Choreoathetosis associated with cervical dystonia as clinical presentation of thyrotoxicosis: A rare condition

    S.C.B. Casagrande, S.M.C.d.A. e Silva (São Paulo, Brazil)

  • Chronic acquired hepatocerebral degeneration: Efficacy of liver transplatation in 10 patients

    J. Martins, J. Alves, S. Cavaco, J. Gandara, S. Ferreira, H. Pessegueiro, M. Magalhães (Porto, Portugal)

  • Chronic cerebral hypoperfusion accelerates cognitive dysfunction and microvascular impairment in the MPTP mouse model of Parkinson’s disease

    H. Tang, R. Zhu, L. Gao, K. Nie, S. Feng, Z. Duan, Y. Zhang, X. Zhao, L. Wang, J. Zhao, Z. Huang, Y. Zhang, L. Wang (Guangzhou, People's Republic of China)

  • Chronic directional subthalamic nucleus deep brain stimulation in Parkinson’s disease – A pilot study

    P. Reker, T.A. Dembek, A. Gierich, J. Wirths, H.S. Dafsari, J. Roediger, M.T. Barbe, L. Timmermann, V. Visser-Vandewalle (Cologne, Germany)

  • Chronic levodopa treatment accelerates the disorders of circadian rhythm in 6-OHDA induced Parkinson’s disease model

    S. Li, Y. Wang, W. Liu, D. Lv, C. Liu (Suzhou, People's Republic of China)

  • Ciprofloxacin as the cause of syndroma extrapiramidale

    D. Imamovic, N. Subasic, A. Nakicevic, E. Suljic (Sarajevo, Bosnia and Herzegowina)

  • Circadian dysfunction in Parkinson’s disease: Effects on impaired gait initiation and locomotion

    L. Alibiglou, J. Stewart, G. Bachman, C. Cooper, L. Liu, S. Ancoli-Israel (Chicago, IL, USA)

  • Circulatory levels of BDNF correlate with cognitive deficits in people with Parkinson’s disease

    H. Khalil, M.A. Alomari, O.F. Khabour, A. Al-Hieshan, J.A. Bajwa (Irbid, Jordan)

  • Classification and recommendation of nonpharmacological therapies for Parkinson’s disease

    T.T.C. Capato, C.H. Fen, E.R. Barbosa (São Paulo, Brazil)

  • Clinical and analytical validation of novel autosomal recessive ataxia mutations identified from whole exome sequencing

    S. Shakya, R. Kumari, A.K. Srivastava, D. Dash, A. Takkar, I. Singh, A. Garg, M. Mukerji, M. Faruq (New Delhi, India)

  • Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population

    M.A. Ramírez-García, D.J. Dávila-Ortiz de Montellano, P. Yescas-Gómez, A. Ochoa-Morales, C. Boll, M.E. Alonso-Vilatela (Mexico City, Mexico)

  • Clinical and biological predictors of excessive daytime sleepiness in early Parkinson’s disease

    T. Simuni, J. Long, C. Caspell-Garcia, C.S. Coffey, W. Oertel, S. Lasch, K. Marek, On behalf of the PPMI Sleep Working Group (Chicago, IL, USA)

  • Clinical and biological predictors of time to initiation of symptomatic therapy in early Parkinson’s disease

    T. Simuni, J. Long, C. Caspell-Garcia, C.S. Coffey, S. Lasch, C. Tanner, D. Jennings, K. Kieburtz, K. Marek, On behalf of the PPMI Investigators (Chicago, IL, USA)

  • Clinical and genetic analyses in a cohort of the Taiwanese patients with apparently sporadic pure spastic paraplegia

    Y.Y. Chang, Y.F. Chen, T.H. Yeh, Y.R. Wu, C.H. Tsai, Y.C. Chang, W.J. Hwang, H.C. Kuo, C.C. Huang, C.C. Lin, Y.Y. Jian, H.C. Shen, C.S. Lu, M.Y. Lan (Kaohsiung, Taiwan)

  • Clinical and imaging characteristics of spinocerebellar ataxia type 14 defined in a German multi-center sample

    T. Schmitz-Hübsch, S. Lux, A.U. Brandt, P. Bauer, E. Schlapakow, S. Greschus, H. Gärtner, M.E. Kirlangic, V. Gras, D. Timmann, M. Synofzik, N. Shah, L. Schöls, U. Kopp, T. Oberwahrenbrock, H. Zimmermann, C. Pfueller, E.M. Kadas, M. Rönnefarth, A. Grosch, M. Endres, T. Klockgether, K. Amunts, F. Paul, S. Doss, M. Minnerop (Berlin, Germany)

  • Clinical and imaging deterioration of a mild case of Wilson’s disease after chelation therapy

    C. Kleoniki, K. Spiridon, T. Cristos, K. Aristidis (Ioannina, Greece)

  • Clinical and instrumental features of multiple system atrophy with laryngeal stridor

    M. Todisco, R. Zangaglia, B. Minafra, M. Terzaghi, E. Alfonsi, P. Vitali, C. Pacchetti (Pavia, Italy)

  • Clinical and instrumental gait analysis study of fear of falling in Parkinson’s disease patients

    P.C. Gordon, J.B. Ferraz, L.M. Medeiros, L.F.R. Oliveira, D.K. Amado, A.M. Lima Neto, M.S.G. Rocha (Sao Paulo, Brazil)

  • Clinical and molecular features of DYT1 primary dystonia in a Peruvian population

    M. Inca-Martinez, K. Milla-Neyra, C.C. Cosentino, N. Mori, V. Marca, M. Flores, E. Guevara-Silva, Y. Nuñez-Coronado, C.M. Vasquez, L. Torres-Ramirez, P. Mazzetti, M. Cornejo-Olivas (Lima, Peru)

  • Clinical and MRI-characteristics of drug-induced parkinsonism in Uzbekistan

    A. Umarov, A. Prokhorova, G. Rakhimbaeva, K. Mirzaeva, N. Tuychibaeva (Tashkent, Uzbekistan)

  • Clinical and neuroimaging correlations in early manifest Huntington’s disease patients: Default mode network properties according to resting-state functional MRI

    Y.A. Seliverstov, E.V. Seliverstova, S.A. Klyushnikov, R.N. Konovalov, S.N. Illarioshkin (Moscow, Russia)

  • Clinical and neuroimaging outcomes up to 18 years after fetal tissue transplant for Parkinson’s disease

    C. Henchcliffe, J. Carter, A. Hanineva, Y. Kang, J. Babich, S.M. Gollomp, A.P. Strafella, A. Fasano, L.D. Ravdin, N. Hellmers, C. McRae (New York, NY, USA)

  • Clinical and polysomnographic features correlates to sleep-disordered breathing in multiple system atrophy

    B. Cao, Q. Wei, R. Ou, B. Zhao, T. Hu, H. Shang (Chengdu, People's Republic of China)

  • Clinical aspects of postural instability in Parkinson’s disease

    T.S. Lovtsova, A.F. Vasilenko (Chelyabinsk, Russia)

  • Clinical benefits of vestibular rehabilitation in neurodegenerative diseases

    B.S. Zeigelboim, G.B. Santos, H.A.G. Teive, M.I.R. Severiano, C.M. Porto (Curitiba, Brazil)

  • Clinical characteristics and natural history of oromandibular dystonia

    L. Scorr, S. Factor, H. Jinnah (Atlanta, GA, USA)

  • Clinical characteristics of Parkinson’s disease and essential tremor patients undergoing deep brain stimulation surgery: Five-year data from Columbia University Medical Center (2009 – 2014)

    M. Kestenbaum, D. Robakis, B. Ford, R.N. Alcalay, E.D. Louis (Tel Aviv, Israel)

  • Clinical characterization of pramipexole induced edema in Parkinson’s disease (PD). Is it always the best option discontinue the treatment?

    E. Urrea-Mendoza, F.J. Revilla (Greenville, SC, USA)

  • Clinical correlates of depression and anxiety in patients with Parkinson’s disease

    H.D. Hambardzumyan, H.M. Manvelyan (Yerevan, Armenia)

  • Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea

    A. Robichaux-Viehoever, A. Ananth, Y.M. Kim, A. Hanson-Kahn, R. Cox, G. Enns, J. Strober, M. Willing, B. Schlaggar, J. Bernstein, Y. Wu (San Francisco, CA, USA)

  • Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

    N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

  • Clinical effects of pallidal stimulation in dystonia are quantitatively related to intracortical inhibition

    A. Fecíková, V. Cejka, V. Capek, F. Ruzicka, V. Bocek, D. Štastná, I. Štetkárová, D. Urgošík, R. Jech (Praha, Czech Republic)

  • Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson’s disease: A prospective study

    T. Kitta, I. Yabe, Y. Kanno, H. Chiba, K. Moriya, I. Takahashi, M. Matsushima, H. Sasaki, N. Shinohara (Sapporo, Japan)

  • Clinical exome sequencing – diagnostic yield in a sample of German patients with Parkinson’s disease

    B. Schormair, G. Machetanz, B. Mollenhauer, C. Trenkwalder, J. Winkelmann (Neuherberg, Germany)

  • Clinical features of Parkinson’s disease patients developing stridor with acute respiratory failure

    J. Tashiro, S. Hamada, H. Soma, M. Nonaka, S. Honma, K. Hamada, A. Takei, F. Moriwaka, K. Tashiro (Sapporo, Japan)

  • Clinical outcome of constant current deep brain stimulation in patients with medication-refractory essential tremor

    A. Rezaei Haddad, K. Ashkan (Coventry, United Kingdom)

  • Clinical outcome of subthalamic deep brain stimulation in Parkinson’s disease – The Helsinki experience

    M. Koivu, A. Huotarinen, F. Scheperjans, R. Kivisaari, E. Pekkonen (Helsinki, Finland)

  • Clinical outcomes of pallidal and subthalamic nucleus deep brain stimulation in isolated cranial and cranio-cervical dystonia

    N.S. Luthra, K.A. Dodenhoff, M. San Luciano, M.M. Volz, S.L. Heath, P.A. Starr, J.L. Ostrem (San Francisco, CA, USA)

  • Clinical phenotype (motor and neuropsychological presentation) and neuroimaging in Sardinian patients affected by atypical parkinsonisms, carriers of 20-22 repeats of C9ORF72 hexanucleotide expansion

    G. Orofino, A. Cannas, P. Solla, M.M. Mascia, M.R. Murru, G. Borghero (Monserrato, Italy)

  • Clinical phenotype of Parkinsonian patients with α-synuclein mutation: Our case report and review of the literature

    P. Nigro, N. Tambasco, M. Romoli, S. Simoni, E. Sacchini, E. Brahimi, E. Marsili, F. Ripandelli, P. Prontera, P. Calabresi (Perugia, Italy)

  • Clinical predictors of airway protective dysfunction in Parkinson’s disease

    M.S. Troche, A.E. Brandimore, B. Schumann, M.S. Okun, K.W. Hegland (New York, NY, USA)

  • Clinical predictors of progressive supranuclear palsy (PSP) pathology in PSP syndrome

    I. Aiba, Y. Saito, Y. Yokokawa, M. Kenjo, T. Katayama, R. Hashimoto, S. Sakakibara, A. Inukai, M. Mimuro, Y. Iwasaki, M. Yoshida (Nagoya, Japan)

  • Clinical presentation and genetic characteristics of Huntingtons disease in Croatia: Thirty years of experience

    M. Relja, I. Jurjevic, K. Blazina, V. Miletic, N. Klepac (Zagreb, Croatia)

  • Clinical presentations of 2 Parkin / lysosomal storage disorder heterozygotes with Parkinson’s disease

    M. Barkhuizen, D.G. Anderson, A.F. Grobler, S.J. Lubbe, H.R. Morris (Potchefstroom, South Africa)

  • Clinical profile and outcome of hospitalized patients with Parkinson’s disease

    P. Chatterjee, K. Chatterjee, R. Banerjee, S. Choudhury, B. Mondal, M. Ummekulsum, S.S. Jha, S. Chatterjee, S.S. Anand, H. Kumar (Kolkata, India)

  • Clinical profile of Parkinson’s disease at the neurology department of Point G Teaching Hospital

    T. Coulibaly, A.S. Sissoko, T. Coulibaly, L. Guida, K. Mamadou, G.C. Oumar (Bamako, Mali)

  • Clinical profile of patients with writer’s cramp

    H.S. Kaleagasi, O. Dogu (Mersin, Turkey)

  • Clinical profile of Wilson’s disease at Yangon General Hospital, Myanmar

    S.M.M. Aye, K.M.P.P. Kyaw, Z. Myint Shwe, O. Ohnmar, Y.M. Aye, W.M. Thit (Yangon, Myanmar)

  • Clinically ‘slight’ bradykinesia in Parkinson’s disease is accurately detected using evolutionary computation analysis of finger tapping

    J.E. Alty, J. Cosgrove, M.A. Lones, S.L. Smith, K. Possin, N. Schuff, S. Jamieson (Leeds, United Kingdom)

  • Clinico-genetic correlation in Indian spinocerebellar ataxia (SCA1) patients

    A. Takkar, I. Ahmed, S. Shakya, V. Suroliya, R. Singh, A. Sonkar, A.K. Srivastava, M. Faruq (New Delhi, India)

  • Clinicopathological characteristics of co-existant Parkinson’s disease and corticobasal degeneration: A case study

    K. Andruska, C. Kilbane, E. Plowey, K. Poston (Stanford, CA, USA)

  • Clusterin CSF levels in differential diagnosis of neurodegenerative disorders

    M. Frolova, H. Prikrylova Vranova, E. Henykova, J. Mares, M. Kaiserova, K. Mensikova, M. Vastik, P. Hlustik, J. Zapletalova, M. Strnad, D. Stejskal, P. Kanovsky (Olomouc, Czech Republic)

  • Co-occurrence of two triplet repeat associated SCA mutations: A dilemma in clinical diagnosis, prognosis and genetic counselling and clinical significance

    A.K. Srivastava, S. Shkaya, M. Faruq, V. Suroliya, V. Goyal, K. Prasad (New Delhi, India)

  • Coding and non-coding glucocerebrosidase variants have an impact on cognitive decline in Parkinson’s disease

    C. Schulte, I. Liepelt-Scarfone, C.E. Hagen, A.K. Hauser, K. Brockmann, T. Gasser, J.B. Schulz, K. Reetz, S. Gräber, B. Mollenhauer, C. Trenkwalder, K. Witt, N. Schmidt, R. Dodel, M. Balzer-Geldsetzer, U. Wüllner, T. Klockgether, A. Spottke, A. Storch, H.U. Wittchen, O. Riedel, S. Baudrexel, E. Kalbe, D. Berg, M.M. Mielke (Tübingen, Germany)

  • Cognition and amyloid biomarker status in non-demented patients with Parkinson’s disease patients (PD) with or without subjective cognitive decline (SCD)

    I. Liepelt-Scarfone, F. Klumpp, W. Maetzler, S. Nussbaum, M. Timmers, G. Salvadore, M. Albers, K. Michaelis, Z. Tkaczynska, J. Streffer, D. Berg (Tübingen, Germany)

  • Cognition, vision and visuo-cognition in gait in Parkinson’s disease

    S. Stuart, B. Galna, S. Lord, L. Rochester (Newcastle upon Tyne, United Kingdom)

  • Cognitive and behavioral problems in children and adolescents with myoclonus dystonia

    M.A. Coenen, H. Eggink, H. van den Berg, J.M. Spikman, M.A. Tijssen (Groningen, Netherlands)

  • Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension

    K.E. McDonell, C.A. Shibao, I. Biagginoi, D. Robertson, D.O. Claassen (Nashville, TN, USA)

  • Cognitive and depressive behavior changes in aged mice with heterozygous deletions of VMAT2 or of DAT

    K. Ma, J. Huang, L. Liu, H. Jiang, X. Xu, C. Han, Y. Shen, Y. Xia, S. Guo, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

  • Cognitive and psychiatric outcome 3 years after bilateral deep brain stimulation of the globus pallidus pars interna versus subthalamic nucleus for Parkinson’s disease

    J.A. Boel, V.J.J. Odekerken, G.J. Geurtsen, B.A. Schmand, M. Figee, R.J. de Haan, P. van den Munckhof, P.R. Schuurman, R.M.A. de Bie, The NSTAPS Study Group (Amsterdam, Netherlands)

  • Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

    R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

  • Cognitive change following deep brain stimulation in patients with movement disorders

    J. Khan, Z. Quamhawi, Y.F. Tai, P.G. Bain, D. Nandi, S. Gunning, N. Pavese (London, United Kingdom)

  • Cognitive complaint in Parkinson’s disease patients with normal cognition

    R.F. Purri, L. Brennan, J. Rick, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J.E. Duda, J.F. Morley, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

  • Cognitive decline in Parkinson’s disease: Impact on quality of life of caregivers

    R.A. Lawson, A.J. Yarnall, G.W. Duncan, F. Johnston, T.K. Khoo, D. Collerton, J.P. Taylor, D.J. Burn (Newcastle upon Tyne, United Kingdom)

  • Cognitive deficits in Parkinson’s disease: A preliminary study of neuropsychological profiles

    R.J. Giannaula, P.G. Sanz, J.C. Maiques, M.B. Seijas, M.J. González Aguilar, L. Grasso (Buenos Aires, Argentina)

  • Cognitive development in individuals with mild Parkinsonian signs

    S. Lerche, K. Brockmann, I. Wurster, A. Pilotto, U. Sünkel, V. Herbst, B. Brixx, A.K. von Thaler, F. Metzger, G. Eschweiler, W. Maetzler, D. Berg (Tübingen, Germany)

  • Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

    E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

  • Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

    E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard (Manchester, United Kingdom)

  • Cognitive function and self-reported depressive symptoms in a population-based cohort to study non-motor-symptoms of Parkinson’s disease

    E.J. Vollstedt, K. Hückelheim, S. Tunc, J. Hampf, C. Kritzinger, M. Kasten, C. Klein (Luebeck, Germany)

  • Cognitive functioning in Parkinson’s disease and Parkinson plus syndrome

    S. Mina, V.K. Verma, K.S. Anand (New Delhi, India)

  • Cognitive impairment in Huntington’s disease

    N. Kamble, N. Netravathi, K. Kumar, S. Jain, P.K. Pal (Bangalore, India)

  • Cognitive impairment in Parkinson’s disease

    B. Kurbanov (Tashkent, Uzbekistan)

  • Cognitive impairment in patients with progressive supranuclear palsy and multiple system atrophy

    M. Vecerkova, M. Kaiserova, L. Hvizdosova, S. Kurcova, P. Kanovsky (Olomouc, Czech Republic)

  • Cognitive impairments in children with tic disorders and Tourette syndrome

    D. Aminova (Tashkent, Uzbekistan)

  • Cognitive outcome in the patients with Parkinson’s disease one year after subthalamic implants in Taiwan

    Y.F. Chen, C.C. Chang, W.F. Chen, F.Y. Shih, M.Y. Lan, T.K. Lin, Y.F. Chen, Y.Y. Chang (Kaohsiung, Taiwan)

  • Cognitive profile in the Parkinsonian variant of multiple system atrophy: Findings from a Tunisian cohort

    A. Nasri, M. Ben Djebara, I. Kacem, Y. Sidhom, A. Gargouri, R. Gouider (Tunis, Tunisia)

  • Cognitive profile of Filipino patients with X-linked dystonia parkinsonism

    J.E.C. Bautista, R.D.G. Jamora, L.K. Ledesma, L.V. Lee, R.L. Rosales, C.C.E. Diesta, A. Domingo (Quezon City, Philippines)

  • Coin rotation as strongest predictor of buttoning in Parkinson’s: A multicenter study demonstrating the everyday impact of limb-kinetic apraxia

    T. Foki, T. Vanbellingen, C. Lungu, W. Pirker, S. Bohlhalter, T. Nyffeler, J. Kraemmer, D. Haubenberger, F.P.S. Fischmeister, E. Auff, M. Hallett, R. Beisteiner (Vienna, Austria)

  • Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease

    C. Ruffmann, I. Poggiolini, N. Bengoa-Vergniory, F. Baig, M. Rolinski, J. Klein, M.T. Hu, R. Wade-Martins, J. Alegre-Abarrategui, L. Parkkinen (Oxford, United Kingdom)

  • Colonic microbiome in Korean patients with Parkinson’s disease

    D. Lee, Y.N. Kwon, T.B. Ahn (Seoul, Korea)

  • Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms

    A. Turakhanov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

  • Combined effects of visual and auditory cues on gait initiation in Parkinson’s disease

    T. Hashimoto, H. Sato (Matsumoto, Japan)

  • Combined imaging markers increase accuracy when predicting real life disease onset in Huntington’s disease

    S.L. Mason, R. Daws, R.A. Barker, A.D. Hampshire (Cambridge, United Kingdom)

  • Combined pallidal and thalamic stimulation for multifocal primary dystonia with prominent writers’ cramp

    A. Wloch, M. Abdallat, G. Lütjens, C. Schrader, J.K. Krauss (Hannover, Germany)

  • Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial

    D. Weiss, G. Naros, C. Meisner, R. Krüger, A. Gharabaghi (Tübingen, Germany)

  • Communication and language skills in Huntington’s disease

    Y. Manor, D. Shpunt, S. Naor, L. Frydman, A. Gad, A. Ezra, A. Migirov, J. Knaani, A. Socher, T. Gurevich (Tel-Aviv, Israel)

  • Comorbid conditions associated with Parkinson´s disease: A longitudinal study

    D. Santos García, E. Suarez Castro, I. Expósito, T. de Deus, C. Tuñas, D. Núñez Arias, Á. Aneiros, M. López Fernández, J. Naveiro, J. Abella, M.A. Llaneza, V. Vilas, M. Macías (Ferrol, Spain)

  • Comorbidity and Parkinson’s disease phenotype, dopaminergic function and CSF biomarkers

    T. Yousaf, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

  • Comparative analysis of clinical and neuroimaging features of parkinsonism and dementia of Alzheimer’s type

    D. Tolibov, G. Rakhimbaeva (Tashkent, Uzbekistan)

  • Comparative analysis of freezing of gait in distinct parkinsonism types by diffusion tensor imagining and cognitive profiles

    H. Onder, E.S. Topcuoglu, A.C. Has, K.K. Oguz, B. Elibol (Ankara, Turkey)

  • Comparative analysis of upper limb motor function and articulation disorder in Parkinson’s disease

    E. Ruzicka, J. Rusz, T. Tykalova, K. Zarubova, R. Krupicka, R. Jech (Prague, Czech Republic)

  • Comparative gait analysis of patients with vascular parkinsonism and idiopathic Parkinson’s disease

    B. Mondal, S. Choudhury, M.U. Kulsum, P. Chatterjee, S. Chatterjee, K. Chatterjee, R. Banerjee, S.S. Jha, S.S. Anand, H. Kumar (Kolkata, India)

  • Comparative study of the substantia nigra echogenicity and 123-I ioflupane SPECT in patients with REM behavior disorder

    J. Mašková, P. Dušek, D. Školoudík, K. Kupka, K. Šonka, V. Ibarburu Lorenzo Y Losada, J. Kubinyi, E. Ruzicka (Praha 2, Czech Republic)

  • Comparative study patients with different clinical forms of Parkinson’s disease

    N.D. Demchuk, T.V. Yakovleva, Y.V. Karakulova (Perm, Russia)

  • Comparing psychosocial risk factors in patients with functional movement disorders and patients with psychogenic non-epileptic seizures

    C.W. Maurer, G.M. Capitan, G. Limachia, K. LaFaver, E. Considine, A. Curran, W.C. LaFrance, M. Hallett (Bethesda, MD, USA)

  • Comparing quality of PD care in a comprehensive clinic to specialist care

    S.A. Factor, L.P. Prizer, F.C. Goldstein, L.M. Trotti, A. Hermida, C. Vaughan (Atlanta, GA, USA)

  • Comparing the characteristics of patients with Parkinson’s disease speech with and without deep brain stimulation

    M.R. Olchik, A.L. Bressanelli, M. Presotto, A.F.S. Schuh, C.R.M. Rieder (Porto Alegre, Brazil)

  • Comparing tremor- and non-tremor effects of ethanol in patients with essential tremor

    J. Thompson-Westra, G. McCrossin, B. Voller, S. Auh, C. Lungu, S. Tinaz, V. Ramchandani, M. Hallett, D. Haubenberger (Bethesda, MD, USA)

  • Comparison of change in the UPDRS verses MDS-UPDRS in a population of Parkinson’s disease (PD) patients treated with deep brain stimulation (DBS)

    S.S. Wang, N.B. Galifianakis, M. San Luciano, P.S. Larson, P.A. Starr, N. Ziman, J.L. Ostrem (San Francisco, CA, USA)

  • Comparison of clinically derived and model based programming parameters of subthalamic nucleus stimulation in Parkinson’s disease

    R. Reese, M.M. Reich, R. Nilunsing, W. Pollet, J. Volkmann (Würzburg, Germany)

  • Comparison of cognitive and neuropsychological manifestations in patients with progressive supranuclear palsy (Psp) and Parkinson’s disease

    M.U. Kulsum, S.S. Anand, S. Chatterjee, P. Chatterjee, B. Mondal, S. Choudhury, K. Chatterjee, R. Banerjee, S.S. Jha, H. Kumar (Kolkata, India)

  • Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease

    W. Li, N.P. Lao-Kaim, A.A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R.A. Barker, P. Piccini (London, United Kingdom)

  • Comparison of DAT scan, cardiac MIBG scintigraphy, and cerebrospinal fluid 5HIAA levels in Parkinsonian syndrome

    R. Sengoku, M. Yamazaki, D. Kaneda, Y. Nishina, A.M. Tokumaru, S. Murayama (Tokyo, Japan)

  • Comparison of effect of variable deep brain stimulation (DBS) frequencies on gait and balance in Parkinson’s disease (PD) patients with either bilateral GPi or STN stimulators employing wearable wireless sensors

    A. Deep, A. Lieberman, R. Dhall, T. Lockhart, C. Frames, S. Shafer, N. Tateuchi, E. Simpson, M. McCauley, N. Krishnamurthi (Phoenix, AZ, USA)

  • Comparison of four DBS lead designs under voltage and current operating modes based on patient specific simulations

    F. Alonso, N. Göransson, P. Zsgimond, K. Wårdell (Linköping, Sweden)

  • Comparison of mental practice and proprioceptive neuromuscular facilitation in sisters with cerebellar atrophy

    C. Bedeschi, D. Guedes, D. Ambrosano (Barueri, Brazil)

  • Comparison of Test Your Memory (TYM) and Montreal Cognitive Assessment (MoCA) measures in Parkinson’s disease

    E.J. Henderson, H. Chu, D.M. Gaunt, A.L. Whone, Y. Ben-Shlomo, V. Lyell (Bristol, United Kingdom)

  • Comparison of the utility of three cognitive scales for MDS Level-I diagnosis of mild cognitive impairment in Parkinson’s disease: MoCA, PD-CRS and ACE-III

    R. Fernandez-Bobadilla, J. Pagonabarraga, J.A. Matias-Guiu, S. Martínez-Horta, A. Horta-Barba, J. Marin-Lahoz, J. Perez-Perez, B. Pascual-Sedano, H. Bejr-Kasem, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

  • Comparison of two protocols for neural induction and cultivation of iPSCs derived neural stem cells

    M.G. Pauly, P. Capetian, B. Meier, V. Krajka, F. Stengel, P. Seibler, C. Klein (Lübeck, Germany)

  • Compensation strategies for gait in Parkinson’s disease

    S.C. Lidstone, A. Fasano, M. Hallett, A. Nieuwboer, E. Ruzicka, B.A. Bloem (Toronto, ON, Canada)

  • Composite autonomic symptom scale-31 (COMPASS-31) is useful for evaluation of autonomic dysfunction in patients with parkinsonism

    Y. Kim, J.M. Seok, H.J. Kim, J. Youn, B.J. Kim, J.W. Cho (Seoul, Korea)

  • Comprehensive motor and non-motor staging system in Parkinson’s disease: Results from a global cross-sectional study

    C. Rodriguez-Blazquez, A. Rizos, K.R. Chaudhuri, P. Martinez-Martin, NILS, EUROPAR and MDS Non-Motor PD Study Groups (Madrid, Spain)

  • Computational analysis of expression profiling data in a neuronal model of X-linked dystonia-parkinsonism

    A. Domingo, A. David, G. Karen, L.V. Lee, R. Rosales, R.D. Jamora, R. Shamir, C. Klein, A. Westenberger (Lübeck, Germany)

  • Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease

    C. Mahapatra, R. Manchanda (Mumbai, India)

  • Computer uses and difficulties in Parkinson’s disease

    Z. Katsarou, M. Plotnik, G. Zeilig, A. Gottlieb, R. Kizony, S. Bostantjopoulou (Thessaloniki, Greece)

  • Conjugal Parkinson´s disease – Real or chance?

    B. Balint, R. Erro, F. Brugger, A. Batla, E. Antelmi, C. Ganos, K.P. Bhatia (London, United Kingdom)

  • Consolidation of learning and memory in Parkinson’s disease

    M.E. Sharp, K. Duncan, K. Foerde, R. Kahane, D. Shohamy (New York City, NY, USA)

  • Constant-current stimulation in Parkinson’s disease patients

    P. Amami, M. Mascia, L. Romito, A. Albanese (Rozzano, Italy)

  • Constipation in early de novo Parkinson’s disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers

    G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

  • Construct validity of Moca test in a sample of patients with Parkinson´s disease in Bogotá and Cali – Colombia

    B.E. Muñoz, O. Bernal, A. Castillo, J.L. Orozco (Cali, Colombia)

  • Construction of a levodopa-response index from wearable sensors for quantifying Parkinson’s disease motor functions: Preliminary results

    M. Memedi, D. Nyholm, J. Westin, M. Senek, A. Medvedev, H. Askmark, S.M. Aquilonius, F. Bergquist, R. Constantinescu, F. Ohlsson, J. Spira, S. Lycke, A. Ericsson (Falun, Sweden)

  • Consumption of Yerba Mate (Ilex Paraguariensis) in Parkinson’s disease patients from Uruguay

    I. Amorín, A. Lescano, N. Ramírez, V. Raggio, R. Buzó (Montevideo, Uruguay)

  • Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

    R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

  • Contributions of sensorial feedback to gait in Parkinson’s disease

    F.A. Barbieri, L.T.B. Gobbi, P.C.R. Santos, R. Vitório, L. Simieli, D. Orcioli-Silva, M.B. Pestana, C.M. Fiorelli, Q. Almeida (Bauru, Brazil)

  • Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

    S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

  • Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns

    J. Morgan, M. Stacy, R. Rubens, S. Khanna, S. Gupta (Augusta, GA, USA)

  • Coping styles and their influence on outcomes in Parkinson’s disease

    K.M. Sundvick, F. Kassam, N. Dispirito, E. Book, S. Cresswell (Vancovuer, BC, Canada)

  • Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis

    A. Pal, B.R. Thapa, R.K. Vasishta, R. Prasad (Chandigarh, India)

  • Core set of measures of balance for people with multiple sclerosis and cerebellar ataxia

    S.J. Winser, C.M. Smith, L.A. Hale, L.S. Claydon, S.L. Whitney, B. Klatt, J. Mottershead, I. Zaydan, R. Heyman, S. Winser (Dunedin, New Zealand)

  • Corpus callosum thickness and area in Parkinson’s disease

    I.O. Bledsoe, D. Merkitch, G. Stebbins, B. Bernard, J.G. Goldman (Chicago, IL, USA)

  • Correlation among DNA methylation status and LINE-1 expression in rat brain

    S. Mukherjee, K. Upadhyaya, D. Sharma (New Delhi, India)

  • Correlation analysis for postural instability and autonomic dysfunction in patients with Parkinson’s disease

    S. You, S.H. Lim, H. Lee, H.A. Kim (Dague, Korea)

  • Correlation between neuro-behavioral symptoms, cognition and gait in patients with dementia with Lewy bodies (DLB)

    B. Tousi, L. Mourany (Cleveland, OH, USA)

  • Correlation between Parkinson’s disease and malignant tumors

    E. Binaghi, M.M. Mascia, P. Solla, M. Meloni, R. Farris, D. Ciaccio, G. Orofino, F. Marrosu, A. Cannas (Cagliari, Italy)

  • Correlation between self-perceived balance confidence, postural control, gait and quality of life of individuals with Parkinson’s disease

    J.E. Pompeu, K.G. Silva, T.B. Freitas, F. Doná, C. Torriani-Pasin, R.A. Nuvolini (São Paulo, Brazil)

  • Correlation between tremor severity of essential tremor and perpendicular displacement in digital spiral analysis

    K.H. Chen, Y.J. Chen, P.C. Lin, B.S. Yang, C.H. Lin, R.M. Wu (Hsin-Chu, Taiwan)

  • Correlations among motor, cognitive, and neuropsychiatric symptoms in Parkinson’s disease without dementia

    M. Gang, Y. Nishio, T. Baba, A. Takeda, E. Mori (Sendai, Japan)

  • Cortical and subcortical contribution in the production of reaching movements in Parkinson’s disease

    A. Canessa, N.G. Pozzi, G. Arnulfo, J. Brumberg, F. Steigerwald, M.F. Ghilardi, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

  • Cortical atrophy in cognitively impaired Parkinson’s disease patients

    M.M. Almuqbel, T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, K. Wood, T.L. Pitcher, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Andrson (Christchurch, New Zealand)

  • Cortical excitability in patients with Parkinson’s disease on levodopa carbidopa intestinal gel thereapy

    S.D. Kim, S. Vucic, N. Mahant, M.C. Kiernan, V.S.C. Fung (Sydney, Australia)

  • Cortical grey matter atrophy in the motor system in Friedreich ataxia: The IMAGE-FRDA study

    I. Harding, L. Selvadurai, L. Corben, M. Stagnitti, E. Storey, G. Egan, M. Delatycki, N. Georgiou-Karistianis (Melbourne, Australia)

  • Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

    A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)

  • Cortical phase amplitude coupling (PAC) identifies patterns in clinical states of Parkinson’s disease (PD) using magnetoencephalography (MEG)

    E. Peña, S.A. Mian, L. Rosedahl, F.A.I. Mohammed, T.M. Mohammad, M.D. Johnson, J.A. Bajwa (Minneapolis, MN, USA)

  • Cortical role in the freezing of gait in Parkinson’s disease

    M. Mihara, H. Otomune, H. Fujimoto, K. Konaka, Y. Watanabe, H. Mochizuki (Suita, Japan)

  • Cortical thinning associated with mild cognitive impairment in Parkinson’s disease

    S. Galantucci, F. Agosta, T. Stojkovic, I. Petrovic, E. Stefanova, E. Canu, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)

  • Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

    M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)

  • Could smell test differ from scans without evidence of dopaminergic deficit and Parkinson’s disease?

    S.J. Kang, J.Y. Ahn, H.T. Kim (Seoul, Korea)

  • Could tonic chin electromyogram density be a potential marker for differentiating atypical Parkinsonian syndromes from Parkinson’s disease among alpha-synucleinopathies?

    Y. Wang, K.P. Xiong, Y. Shen, P.C. He, C.J. Mao, J. Li, J.Y. Huang, C.F. Liu (Suzhou, People's Republic of China)

  • Counteracting PINK1/parkin deficiency by activating alternative mitophagic pathway: a potential therapeutic intervention for Parkinson’s disease

    B. Koentjoro, J.S. Park, C.M. Sue (Sydney, Australia)

  • Coupling between visual information and body sway in people with Parkinson’s disease

    C.F. Cruz, L.A.O.A. Nóbrega, E. Okamoto, M.E.P. Piemonte, J.A. Barela (São Paulo, Brazil)

  • Creatine for patients with Parkinson’s disease: A meta-analysis

    A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

  • Creative thinking and parkinsonism: Preliminary clinical data on the role of frontal area

    M. Canesi, M. Rusconi, E. Cereda, F. Moroni, A. Ranghetti, V. Cereda, G. Pezzoli (Milano, Italy)

  • Creativity related to dopaminergic treatment. A multicenter study

    P.J. Garcia Ruiz, J.C. Martinez Castrillo, L. Vela (Madrid, Spain)

  • Creutzfeldt-Jakob disease presenting predominantly with movement disorder: A case report

    A.A. Sann, M.M. Zaw, T.L. Choie (Yangon, Myanmar)

  • Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease

    D.T. Stephenson, S. Arneric, D. Babcock, P. Cole, T. Comery, M.F. Gordon, D. Grosset, D. Hill, S.Z. Imam, C.R. Jarecke, V. Kern, D. Matthews, R. Meibach, K. Romero, A. Roach, D. Russell, J. Seibyl, P. Sherwin, B.A. Sieber, L. Slicker, C. Sur, K. Marek (Tucson, AZ, USA)

  • Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease

    K. Romero, D. Burn, M. Hu, A. Yarnell, C. Williams Gray, K. Marek, D. Grosset, M. Sutherland, M. Isaac, A. Bhattaram, V. Sinha, M.F. Gordon, P. Muglia, L. Slicker, W. Hirst, M. Facheris, J. Posener, M. Bani, B. Corrigan, R. Schindler, K. Tsai, T. Nicholas, J. Cedarbaum, J. Gallagher, S. Ford, E. Avilex, V. Kern, S. Arneric, D. Stephenson, A. Roach (Tucson, AZ, USA)

  • CSF inflammatory and cell death biomarkers in Huntington’s disease – An exploratory cross-sectional study

    F.B. Rodrigues, L. Byrne, S.J. Tabrizi, H. Zetterberg, E. Wild (London, United Kingdom)

  • CSF level of chromogranin A in amyotrophic lateral sclerosis

    M. Kaiserova, P. Otruba, K. Mensikova, Z. Grambalova, H. Prikrylova Vranova, J. Mares, D. Stejskal, P. Kanovsky (Olomouc, Czech Republic)

  • Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats

    N. Sharma, B. Nehru (Chandigarh, India)

  • Cyclic glycine-proline increased in the cerebrospinal fluid of Parkinson’s patients after supplementation of blackcurrant anthocyanins: Potential biomarker for treatment

    J. Guan, Y. Alamri, D. Fan, M. MacAskill, T. Anderson (Auckland, New Zealand)

  • Cytokines in CSF and plasma as potential biomarkers for PD cognitive impairment

    M. Delgado-Alvarado, B. Gago, A. Gorostidi, H. Jiménez-Urbieta, J. Ruiz-Martínez, A. Bergaretxe-Yarza, J.F. Martí-Massó, P. Martínez-Lage, A. Izagirre, A. Oregi, L. Sepúlveda, M.C. Rodríguez-Oroz (San Sebastián, Spain)

Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley